Ignite Creation Date:
2024-10-25 @ 8:00 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06573060
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
Glycemic Variability Gut Microbiota and Prognosis in T2DM With ACS
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Impact of Glycemic Variability and Gut Microbiota and Metabolites on the Prognosis of Patients With Type 2 Diabetes Mellitus Combined With Acute Coronary Syndrome
Status:
RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with type 2 diabetes mellitus T2DM diagnosed with acute coronary syndrome ACS by coronary angiography in the Second Affiliated Hospital of Nanchang University were consecutively included in a prospective cohort study During the acute phase of ACS blood glucose was monitored using a continuous glucose monitoring system CGM for 14 days and for patients who had been hospitalised for less than 14 days they continued to wear the CGM for monitoring blood glucose until 14 days after discharge During this period stool and serum samples were analysed for multi-omics 16s rRNA sequencing and metabolomics Subsequently a follow-up period of at least 1 year was performed to observe the patients for the occurrence of adverse cardiovascular events MACE during the follow-up period and to assess the impact of glycaemic variability and gut flora and its metabolites on the prognosis of patients with T2DM combined with ACS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None